Phase
Condition
N/ATreatment
Arpraziquantel 150mg dispersible tablet
Clinical Study ID
Ages 24-59 All Genders Accepts Healthy Volunteers
Study Summary
Eligibility Criteria
Inclusion
Living in the designated implementation area since at least 6 months
Aged between 24 - 59 months
Informed consent available
No acute or chronic illness and/or inability to take oral medication
No reported history of seizures
No known allergic response to praziquantel
Study Design
Connect with a study center
Programme National de Lutte Contre les Maladies Tropicales Négligées à Chimiothérapie Préventive (PNLMTN-CP), Ministère de la Santé, de l'Hygiène Publique et de la Couverture Maladie Universelle (MSHPCMU)
Abidjan,
Côte D'IvoireActive - Recruiting
Université Félix Hophouët-Boigny (UFHB), Département de sociologie
Abidjan,
Côte D'IvoireActive - Recruiting
Université Félix Hophouët-Boigny (UFHB), UFR Biosciences
Abidjan,
Côte D'IvoireActive - Recruiting
African Institute for Health and Development (AIHD)
Nairobi,
KenyaSite Not Available
Kenya Medical Research Institute (KEMRI), Eastern and Southern Africa Centre of International Parasite Control (ESACIPAC)
Nairobi,
KenyaSite Not Available
Makerere University, Department of Sociology and Anthropology
Kampala,
UgandaSite Not Available
Vector Borne & Neglected Tropical Disease Control Division, Ministry of Health
Kampala,
UgandaSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.